While preclinical studies suggest that Withania somnifera and its active compounds can modulate pathways related to Alzheimer's disease pathology such as amyloid-beta and inflammation, clinical evidence in humans is currently limited to symptomatic and cognitive improvements in mild cognitive impairment rather than a proven reversal of the disease.
what the evidence does support
Withania somnifera shows preclinical potential in modulating pathways related to Alzheimer's disease pathology and can lead to symptomatic improvements.
Evidence for · 5
Natural Products and Their Neuroprotective Effects in Degenerative Brain Diseases: A Comprehensive Review.
2024 · cited by 19
Discusses how natural compounds like those from Withania somnifera can reduce amyloid-beta and tau pathology as well as combat oxidative stress.
Evidence against · 2
Effect of ashwagandha (
<i>Withania somnifera</i>
) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, placebo-controlled study
2025 · cited by 7
Clinical trials on humans with mild cognitive impairment show improvements in memory and cognition, but fall short of demonstrating a complete reversal of established Alzheimer's pathology.
See more details
More for · 4
<i>Withania somnifera</i> (L.) Dunal, a Potential Source of Phytochemicals for Treating Neurodegenerative Diseases: A Systematic Review.
2024 · cited by 16
Highlights systematic reviews showing Withania somnifera's potential applications in treating neurodegenerative diseases like Alzheimer's.
Preclinical Evidence of <i>Withania somnifera</i> and <i>Cordyceps</i> spp.: Neuroprotective Properties for the Management of Alzheimer's Disease.
Advances in Bioactive Compounds from Plants and Their Applications in Alzheimer's Disease.
2025 · cited by 1
Identifies withanolides from Withania somnifera as multi-target agents that can inhibit Aβ aggregation and reduce tau phosphorylation.
Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer's Disease: Advances and Future Directions.
2026 · cited by 1
Notes that ashwagandha exhibits promising activity in modulating Aβ aggregation and neuroinflammatory pathways in preclinical studies.
More against · 1
Enhancing healthspan with Ashwagandha (Withania somnifera): a comprehensive review of its multifaceted geroprotective benefits.
2025 · cited by 2
Reviews emphasize that clinical evidence mostly supports healthspan benefits and mild cognitive improvements rather than a proven reversal of disease pathology.